Biosig Technologies Net Common Equity Issued/Repurchased 2012-2024 | BSGM
Biosig Technologies net common equity issued/repurchased from 2012 to 2024. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
| Biosig Technologies Annual Net Common Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $4 |
| 2023 | $15 |
| 2022 | $11 |
| 2021 | $10 |
| 2020 | $32 |
| 2019 | $18 |
| 2018 | $12 |
| 2017 | $6 |
| 2016 | $5 |
| 2015 | $5 |
| 2014 | $2 |
| 2013 | $0 |
| 2012 | $N/A |
| 2011 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.033B | $0.000B |
| BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company's first product, PURE EP (tm) System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. | |||